A phase I study of irinotecan administered on a weekly schedule in pediatric patients
- 14 March 2005
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 46 (1), 50-55
- https://doi.org/10.1002/pbc.20355
Abstract
Background The objectives of this study were to determine the maximum tolerated dose (MTD), dose‐limiting toxicities (DLTs), pharmacokinetics, and anti‐tumor effect of irinotecan in pediatric patients with recurrent or refractory malignancies. Procedure Twenty‐three patients between 1 and 21 years of age, with a solid tumor refractory to standard therapy or for which there was no standard therapy were enrolled. Irinotecan was administered over 90 min weekly 4×, every 6 weeks. The initial dose level was 125 mg/m2/day, with subsequent escalations to 160 and 200 mg/m2/day. A MTD was defined in heavily‐pretreated and less‐heavily‐pretreated (≤2 prior chemotherapy regimens, no prior bone marrow transplantation, and no central axis radiation) patients. Pharmacokinetic studies were also performed. Results Neutropenia and diarrhea were the DLTs in heavily pretreated patients; the MTD was 125 mg/m2/day. Neutropenia was the DLT in less‐heavily pretreated; the MTD was 160 mg/m2/day. Five patients had stable disease for two to four cycles including one patient each with rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, and two patients with ependymoma. Irinotecan clearance was greater that that previously reported for children receiving high dose irinotecan. Conclusions The recommended phase II dose of irinotecan administered weekly 4×, every 6 weeks in children with solid tumors is 125 mg/m2/dose for heavily pretreated patients and 160 mg/m2/dose for less heavily pretreated patients.Keywords
This publication has 9 references indexed in Scilit:
- Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in ChildrenJournal of Clinical Oncology, 1999
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998
- Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.Journal of Clinical Oncology, 1997
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.Journal of Clinical Oncology, 1996
- Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumorsCancer Chemotherapy and Pharmacology, 1995
- Phase I and pharmacokinetic trial of weekly CPT-11.Journal of Clinical Oncology, 1993
- A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.Journal of Clinical Oncology, 1992
- Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1991